Publications by authors named "Ardak Zhumagaliyeva"
Article Synopsis
- The study aimed to evaluate the mortality rates of patients with thoracic cancers during the Omicron COVID-19 wave and the impact of vaccinations on their outcomes.
- The research, including data from 346 patients, showed a significantly lower overall mortality of 3.2% compared to earlier pandemic waves, with evidence that booster vaccinations improved protection against hospitalization and death.
- Despite these improvements, around 56.4% of patients experienced delays in cancer treatment, which may negatively impact cancer-related survival rates.
Introduction: Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.
Methods: Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics.
Results: As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis.
Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD.
Multidiscip Respir Med
October 2017
Background: Alpha-1-antitrypsin deficiency (AATD) is an under-diagnosed condition in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to screen for AATD in Kazakh patients with COPD using dried blood spot specimens.
Methods: The alpha1-antitrypsin (AAT) concentration was determined by nephelometry, PCR was used to detect PiS and PiZ alleles; and isoelectric focusing was used to confirm questionable genotype results and detect rare AAT variants.